abrdn plc lowered its stake in STERIS plc (NYSE:STE - Free Report) by 4.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 253,483 shares of the medical equipment provider's stock after selling 10,583 shares during the quarter. abrdn plc owned about 0.26% of STERIS worth $61,122,000 at the end of the most recent quarter.
Several other institutional investors have also bought and sold shares of the stock. Strategic Wealth Investment Group LLC lifted its stake in STERIS by 6.3% during the third quarter. Strategic Wealth Investment Group LLC now owns 4,667 shares of the medical equipment provider's stock valued at $1,100,000 after buying an additional 275 shares in the last quarter. Autumn Glory Partners LLC purchased a new stake in STERIS during the third quarter valued at about $337,000. State of Alaska Department of Revenue lifted its stake in STERIS by 6.9% during the third quarter. State of Alaska Department of Revenue now owns 11,455 shares of the medical equipment provider's stock valued at $2,778,000 after buying an additional 735 shares in the last quarter. GHP Investment Advisors Inc. lifted its stake in STERIS by 1.8% during the third quarter. GHP Investment Advisors Inc. now owns 56,085 shares of the medical equipment provider's stock valued at $13,603,000 after buying an additional 1,015 shares in the last quarter. Finally, Boston Trust Walden Corp lifted its stake in STERIS by 0.3% during the third quarter. Boston Trust Walden Corp now owns 44,912 shares of the medical equipment provider's stock valued at $10,893,000 after buying an additional 118 shares in the last quarter. Institutional investors and hedge funds own 94.69% of the company's stock.
Insider Buying and Selling at STERIS
In other STERIS news, Director Christopher S. Holland sold 473 shares of the stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $239.68, for a total transaction of $113,368.64. Following the transaction, the director now owns 582 shares in the company, valued at $139,493.76. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, CFO Michael J. Tokich sold 23,332 shares of the stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $247.00, for a total value of $5,763,004.00. Following the completion of the sale, the chief financial officer now directly owns 42,930 shares of the company's stock, valued at approximately $10,603,710. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Christopher S. Holland sold 473 shares of the stock in a transaction that occurred on Thursday, August 8th. The shares were sold at an average price of $239.68, for a total value of $113,368.64. Following the completion of the sale, the director now directly owns 582 shares of the company's stock, valued at $139,493.76. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 1.14% of the company's stock.
STERIS Stock Up 0.2 %
NYSE:STE traded up $0.45 during mid-day trading on Wednesday, reaching $224.32. The stock had a trading volume of 135,319 shares, compared to its average volume of 472,704. The business's 50 day moving average is $234.38 and its 200 day moving average is $226.73. STERIS plc has a fifty-two week low of $195.47 and a fifty-two week high of $248.24. The stock has a market cap of $22.12 billion, a P/E ratio of 55.55 and a beta of 0.84. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.33 and a quick ratio of 1.49.
STERIS (NYSE:STE - Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The medical equipment provider reported $2.14 EPS for the quarter, topping analysts' consensus estimates of $1.98 by $0.16. STERIS had a return on equity of 13.85% and a net margin of 7.36%. The firm had revenue of $1.28 billion for the quarter, compared to the consensus estimate of $1.27 billion. During the same quarter in the prior year, the company posted $2.00 earnings per share. The firm's revenue was down .4% on a year-over-year basis. As a group, sell-side analysts predict that STERIS plc will post 9.06 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of analysts have commented on STE shares. StockNews.com lowered shares of STERIS from a "strong-buy" rating to a "buy" rating in a research note on Tuesday. Piper Sandler upgraded STERIS from a "neutral" rating to an "overweight" rating and upped their target price for the company from $230.00 to $260.00 in a report on Thursday, October 24th. Needham & Company LLC reiterated a "hold" rating on shares of STERIS in a report on Thursday, August 8th. JMP Securities reiterated a "market outperform" rating and issued a $265.00 target price on shares of STERIS in a report on Wednesday, August 7th. Finally, KeyCorp upped their target price on STERIS from $255.00 to $265.00 and gave the company an "overweight" rating in a report on Tuesday, September 3rd. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat, STERIS currently has a consensus rating of "Moderate Buy" and a consensus target price of $253.00.
Check Out Our Latest Stock Analysis on STERIS
About STERIS
(
Free Report)
STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.
Recommended Stories
Before you consider STERIS, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and STERIS wasn't on the list.
While STERIS currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
